Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Insulin prices

- PMLiVE

Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia

Cold agglutinin disease affects around 12,000 people in the US, Europe and Japan

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

Eli Lilly and Purdue sign $92.5m deal for pharma manufacturing scholarships

Participating students with be able to compete for a role at the company following graduation

- PMLiVE

QiC Diabetes awards 2022 celebrate UK healthcare excellence

The annual awards recognise the efforts of NHS teams and individuals

- PMLiVE

Novo Nordisk completes acquisition of Forma Therapeutics in deal worth $1.1bn

The acquisition includes a pipeline of haemoglobinopathies including etavopivat

- PMLiVE

Eli Lilly granted fast track designation by FDA for obesity treatment

The company plans to initiate a rolling submission of a new drug application for tirzepatide this year

- PMLiVE

Sanofi and Regeneron’s Dupixent approved by FDA for prurigo nodularis

The two phase 3 trials showed a meaningful reduction in itching

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links